Unlike FLT3 or IDH1/2 mutations, which are potential therapeutic targets in only a subset of patients [2,7], the PI3K/AKT/mTOR pathway demonstrates broad activation across a wide variety of molecular and cytogenetic subtypes of AML in pre-clinical studies [8,9,10,11]. Here, MTOR is linked to acute myeloid leukemia.